GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter
Watch policy updates: Tirzepatide formulations for obesity (branded differently in some approvals) may change insurer policies over time
These arent minor quibbles
A: L-Glutathione, Vitamin-C, and Alpha Lipoic Acid Tablet should be stored in a dry and cool place
doi:10.1146/annurev-med-043024-011141 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al
Treatment With a GLP1R Agonist Over Four Weeks Promotes Weight Loss-Moderated Changes in Frontal-Striatal Brain Structures in Individuals With Mood Disorders